News

Recent news about Panacea Venture and select portfolio companies

September 21, 2023

Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

September 21, 2023

Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

September 20, 2023

Day Zero Diagnostics Announces Completion of $16M Financing Round

DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.

September 20, 2023

Day Zero Diagnostics Announces Completion of $16M Financing Round

DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.

September 19, 2023

Chime Biologics

September 19, 2023

Chime Biologics

September 19, 2023

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development

September 19, 2023

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development

September 6, 2023

MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer

The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.

September 6, 2023

MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer

The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens.